Atsena Therapeutics Releases ATSN-301 Gene Therapy Data

Durham-based biotech company shows successful preclinical testing for its Usher Syndrome Type 1B gene therapy.

Updated on Oct. 30, 2026 in Biotech

Isometric editorial illustration of a DNA double helix and two spherical viral vectors, representing gene therapy molecular structure. — Durham-based Atsena Therapeutics announced positive preclinical data for ATSN-301, a dual-vector gene therapy developed to treat Usher Syndrome Type 1B. AI Illustration. Upload story photo >

Live Poll

Is enough being done to accelerate research for treatments of inherited, currently incurable diseases?

Atsena Therapeutics has released preclinical data for ATSN-301, a gene therapy designed to treat Usher Syndrome Type 1B. The study confirms that the therapy achieves high expression levels without requiring foveal detachment.

Why it matters

The MYO7A gene sequence is too large for a single AAV vector, necessitating this novel dual vector approach. The results indicate a safe profile for future clinical applications.

The therapy uses the AAV.SPR capsid to laterally spread across the retina, bypassing the 4.8 kb packaging limit of standard vectors for the 6.7 kb MYO7A sequence. Six-month studies confirmed no systemic toxicity with retinal-confined biodistribution.

The players

Atsena Therapeutics

A clinical-stage gene therapy company based in Durham that focuses on developing treatments for inherited retinal diseases.

The details

ATSN-301 co-delivers two AAV vectors that recombine at the DNA level to express the full-length MYO7A protein. The therapy reached the macula without damaging the fovea, according to data presented in Hamburg.

October 27-30, 2026: The ESGCT 33rd Annual Congress took place in Hamburg.
October 30, 2026: Atsena Therapeutics officially announced the preclinical findings.
2027: The company plans to submit an Investigational New Drug application.

The Tech Race

This development addresses the historical packaging capacity limit of AAV vectors, which previously prevented the delivery of large genes like MYO7A. It positions Atsena Therapeutics at the forefront of retinal gene therapy by overcoming size constraints that legacy viral vectors could not accommodate.

This research represents a step toward new treatment options for patients with Usher Syndrome Type 1B who currently lack effective gene therapies. The successful preclinical trial suggests a lower risk of systemic side effects, which may eventually lead to safer and more accessible retinal procedures.

The takeaway

The successful use of dual AAV vectors offers a potential path for addressing larger genetic sequences in ocular medicine. Researchers and clinicians should monitor the progress of these recombinatory techniques as they move toward the 2027 regulatory submission.